Financial Performance - Net profit attributable to shareholders rose by 170.42% to CNY 519,948,617.60 for the first nine months of 2024, up from CNY 192,274,739.14 in the same period of 2023[5] - Operating income for the third quarter of 2024 reached CNY 385,512,418.60, a 92.07% increase from CNY 200,713,772.75 in the third quarter of 2023[6] - The company reported a basic earnings per share of CNY 5.87 for the first nine months of 2024, reflecting a 156.33% increase from CNY 2.29 in the same period of 2023[5] - Total operating revenue for the first nine months of 2024 reached ¥974,106,023.82, a significant increase from ¥505,441,166.01 in the same period of 2023, representing an increase of approximately 92.5%[28] - Net profit for the first nine months of 2024 was ¥519,925,252.89, compared to ¥191,426,828.65 in the same period of 2023, reflecting an increase of about 171.5%[28] - Operating profit for the first nine months of 2024 was ¥615,420,483.50, compared to ¥249,147,060.78 in the same period of 2023, marking an increase of around 147.5%[29] - The total profit for the first nine months of 2024 was ¥613,309,935.94, compared to ¥250,102,797.98 in the same period of 2023, reflecting an increase of approximately 144.5%[29] Cash Flow - Cash flow from operating activities increased by 198.12% to CNY 543,021,784.16 for the first nine months of 2024, compared to CNY 182,148,017.93 in the previous year[5] - Operating cash inflow for the first nine months of 2024 reached ¥1,033,433,069.84, a significant increase from ¥504,311,286.45 in the same period of 2023, representing a growth of approximately 104.5%[30] - Net cash flow from operating activities for the first nine months of 2024 was ¥543,021,784.16, compared to ¥182,148,017.93 in the same period of 2023, indicating a year-over-year increase of about 198.5%[30] - Cash inflow from investment activities totaled ¥440,976,164.40 in the first nine months of 2024, up from ¥350,651,972.61 in the same period of 2023, reflecting a growth of approximately 25.7%[31] - Cash inflow from financing activities was ¥70,000,000.00 in the first nine months of 2024, down from ¥332,833,921.17 in the same period of 2023, indicating a decrease of approximately 78.9%[31] - The ending cash and cash equivalents balance as of the end of September 2024 was ¥812,408,426.94, up from ¥461,982,053.16 at the end of September 2023, representing an increase of approximately 75.7%[31] Assets and Liabilities - Total assets increased by 28.96% to CNY 1,849,909,700.30 as of September 30, 2024, compared to CNY 1,434,538,371.98 at the end of 2023[4] - The company's total liabilities decreased, with a consolidated debt-to-asset ratio of 28.84%, down from 33.56% in the previous year[4] - The company's total liabilities stood at ¥533,451,044.56 as of September 30, 2024, up from ¥481,407,169.13, representing an increase of about 10.5%[21] - The equity attributable to shareholders increased significantly to ¥1,317,024,173.75 from ¥953,673,356.15, showing a growth of approximately 38%[21] - Current liabilities totaled ¥285,922,930.46, compared to ¥243,427,152.35 in the previous year, which is an increase of approximately 17%[25] Research and Development - The company plans to expand its product line, focusing on the development of new medical devices and antiviral drugs, which are currently in the capitalization phase[8] - Research and development expenses for 2024 were ¥43,370,119.62, a decrease from ¥61,327,683.97 in 2023, reflecting a reduction of approximately 29%[26] - Research and development expenses for the first nine months of 2024 totaled ¥42,632,127.28, compared to ¥36,166,767.08 in the same period of 2023, showing an increase of approximately 18%[28] Other Financial Metrics - The company's gross profit margin improved, with a weighted average return on net assets of 44.22% based on net profit attributable to shareholders for the first nine months of 2024, up from 32.72% in the same period of 2023[5] - Investment income increased to ¥976,164.40, a rise of 452.44% due to higher financial management returns[9] - Credit impairment losses decreased by 32.93% to -¥2,078,305.89, attributed to improved accounts receivable management and collection efficiency[9] - Income tax expenses surged by 163.41% to ¥88,281,772.38, resulting from expanded sales scale and significant profit growth compared to the same period last year[9] - Non-operating income decreased by 96.12% to ¥46,175.86, primarily due to a reduction in government subsidies unrelated to regular business activities[9] - Non-operating expenses increased by 894.60% to ¥2,168,546.66, mainly due to higher donation expenditures during the period[9] Shareholder Information - The total number of ordinary shares increased from 68,086,000 to 88,511,800, with a significant rise in the number of shares held by major shareholders[12] - The company has implemented an employee stock ownership plan, which was approved by the shareholders' meeting[16] - The company has implemented an employee stock ownership plan, which is currently in progress as of the reporting period[17]
锦波生物(832982) - 2024 Q3 - 季度财报